Immuneering Corporation

Immuneering did not provide quarterly revenue or EPS figures on the call. The main hard numbers discussed were 86% overall survival at nine months in 34 first-line pancreatic cancer patients treated with atebimetinib plus modified gemcitabine/nab-paclitaxel, versus approximately 47% overall survival at nine months for standard of care. Management also reiterated a nine-month median follow-up on that dataset. Cash and cash equivalents were $227.6 million as of September 30, 2025, up from $36.1 million as of December 31, 2024, after a $25 million private placement in August, a $175 million underwritten offering in September, and a $25 million private placement to Sanofi. Management said that, based on current operating plans, cash is expected to fund operations into 2029. Forward-looking milestones included feedback from regulators in 2025, updated ctDNA data in 2026, updated survival data in 2026, and dosing the first patient in the pivotal Phase III PDAC study in mid-2026, pending regulatory feedback; the company also expects to dose the first patient in the Libtayo lung cancer study in 2026.

Benjamin Zeskind framed 2025 as “transformational,” emphasizing the September survival data in pancreatic cancer, the strengthened balance sheet, and the potential for atebimetinib to work across multiple combinations and tumor types. He said the FOLFIRINOX case studies add another “pillar of robustness” to the company’s data and reinforce both the tolerability and optionality of the drug. His tone was highly confident and aspirational, repeatedly calling first-line pancreatic cancer the “top priority” while saying the company believes it is positioned to solve the disease “first and best” in that setting.

Mallory Morales kept the financial update brief and focused on cash. She said the balance sheet improved materially after three financings in August and September: a $25 million private placement, a $175 million underwritten offering, and a $25 million private placement with Sanofi. She reported cash and cash equivalents of $227.6 million at September 30, 2025, versus $36.1 million at December 31, 2024, and said the current operating plan funds the company into 2029.

Analysts asked whether the new pancreatic case studies and tolerability profile change the company’s plans for adjuvant PDAC or 5-FU-based regimens; management said those are possibilities being considered, but not the current priority, which remains first-line PDAC with modified gemcitabine/nab-paclitaxel. Questions also focused on whether the FOLFIRINOX cohort data will be shared soon and whether a compendia listing might follow; management declined to guide timing and said the cohort is still secondary to the main program. On lung cancer, management said the Libtayo study will dose its first patient in 2026, while the Lilly KRAS G12C combination is too early for timing guidance; it also said the 2029 runway funds Phase III PDAC, lung cancer studies, and preclinical pipeline work.